fatty diacid raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-24. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Juice is also able to transfer electricity due to the presence of several ions from the processing. When the electric field is applied to the juice, electric currents are then able to flow into the liquid juice and be transferred around due to the charged molecules in the juice. Therefore, pulsed electric fields are able to inactivate microorganisms, extend shelf life, and reduce the enzymatic activity of the juice while maintaining similar quality as the original, fresh-pressed juice.
Determining the atomic structure of a sample Studying spectral emission lines of the sun and distant galaxies Space exploration Cure monitoring of composites using optical fibers. Estimating weathered wood exposure times using near infrared spectroscopy Measurement of different compounds in food samples by absorption spectroscopy both in visible and infrared spectrum Measurement of toxic compounds in blood samples Non-destructive elemental analysis by X-ray fluorescence Electronic structure research with various spectroscopes Redshift to determine the speed and velocity of a distant object Determining the metabolic structure of a muscle Monitoring dissolved oxygen content in freshwater and marine ecosystems Altering the structure of drugs to improve effectiveness Characterization of proteins Respiratory gas analysis in hospitals Finding the physical properties of a distant star or nearby exoplanet using the Relativistic Doppler effect. In-ovo sexing: spectroscopy allows to determine the sex of the egg while it is hatching. Developed by French and German companies, both countries decided to ban chick culling, mostly done through a macerator, in 2022. Process monitoring in Industrial process control
== Cast == Ruby Lin as Gu Manzhen (顧曼楨) Patrick Tam as Shen Shijun (沈世鈞) Jiang Qinqin as Gu Manlu (顧曼璐) Li Li-chun as Zhu Hongcai (祝鴻才) Hu Ke as Shi Cuizhi (石翠芝) Chang Chang as Xu Shuhui (許叔惠) Xing Minshan as Zhang Yujin (張豫瑾)
As the new Emperor could not exert his constitutional powers until he came of age, a regency was set up by the General Assembly. In the absence of a charismatic figure who could represent a moderate face of power, a series of localized rebellions took place, such as the Cabanagem in Grão-Pará, the Malê Revolt in Salvador, the Balaiada (Maranhão), the Sabinada (Bahia), and the Ragamuffin War, which began in Rio Grande do Sul and was supported by Giuseppe Garibaldi. These emerged from the provinces' dissatisfaction with the central power, coupled with old and latent social tensions peculiar to a vast, slaveholding and newly independent nation state. This period of internal political and social upheaval, which included the Praieira revolt in Pernambuco, was overcome only at the end of the 1840s, years after the end of the regency, which occurred with the premature coronation of Pedro II in 1841. During the last phase of the monarchy, internal political debate centered on the issue of slavery. The Atlantic slave trade was outlawed in 1850, as a result of the British Aberdeen Act and the Eusébio de Queirós Law, but only in May 1888, after a long process of internal mobilization and debate for an ethical and legal dismantling of slavery in the country, was the institution formally abolished with the approval of the Golden Law. The foreign-affairs policies of the monarchy dealt with issues pertaining Brazil's neighboring countries in the Southern Cone.
The extinction of Neanderthals was part of the broader Late Pleistocene megafaunal extinction event. Neanderthals were replaced by modern humans, indicated by the near-complete replacement of Middle Palaeolithic Mousterian stone technology with modern human Upper Palaeolithic Aurignacian stone technology across Europe (the Middle-to-Upper Palaeolithic Transition) from 39,000 to 41,000 years ago. Neanderthals may have persisted in Spain for longer, but the dates of the latest Mousterian and earliest Aurignacian are poorly constrained. In Catalonia and Aragón (northern Spain), the Mousterian may have survived to about 39,000 years ago, and in southern Spain and Gibraltar potentially 32,000 to 35,000 years ago. Similar refuge zones have also been proposed on other temperate European peninsulas, namely Italy, the Balkans, and Crimea. Historically, the cause of extinction of Neanderthals and other archaic humans was viewed under an imperialistic guise, with the superior invading modern humans exterminating and replacing the inferior species.
Sources: en.wikipedia.org
A study on Cryptothecia rubrocincta reveals distinct biochemical compositions in various parts of its thallus, suggesting specialised roles for the compounds present. Specifically, confluentic acid was found exclusively in localised brown flecks within the red and pink zones of the thallus, alongside calcium oxalate monohydrate. This distribution is in contrast to other thallus areas, such as the white zone containing only calcium oxalate dihydrate and the dark red zone with chiodectonic acid, chlorophyll, beta-carotene, and additional calcium oxalate dihydrate in the pink sub-zone. The presence of confluentic acid in specific areas without beta-carotene and chiodectonic acid—both known UV protectants—suggests that confluentic acid plays a different role in the lichen's survival strategy. While the exact function of confluentic acid in these localised brown flecks remains unclear, it is indicated that it is not required for radiation protection. The study also highlights a transition within the lichen from calcium oxalate dihydrate to the more stable monohydrate form, associated with the ageing process and possibly the metabolic activities involving confluentic acid.
=== Graph based === Similarly to string-based methods, the molecular graph can directly be used as input for QSAR models, but usually yield inferior performance compared to descriptor-based QSAR models.
=== 15 January === At least 120 people were killed in an RSF attack on a civilian convoy being escorted by the Sudan Liberation Movement (SLM) and the Gathering of Sudan Liberation Forces (GSLF) near Kabkabiya, North Darfur. Nine people were killed in attacks by the SAF and the RSF on members of the Kanabi community, who mostly originate from Darfur, in Abu Gouta, Gezira State. Fifteen people were killed in an RSF attack on the village of Al-Khizan in Abu Gouta. The Sultan Ali Dinar Palace Museum in El Fasher was shelled by the RSF, causing a fire that heavily damaged the structure and destroyed its contents and furniture.
14 teaching awards from Harvard University, Massachusetts General Hospital and the University of Pennsylvania School of Medicine[2] Named the most influential pathologist in the United States by The Pathologist in 2015[2][6] Inducted into the Association for Diagnostics & Laboratory Medicine (ADLM) Hall of Fame[1] Champion for Innovation Award, Association for Molecular Pathology, 2025[2]
Secondary ion mass spectrometry (SIMS) was one of the first matrix-free desorption/ionization approaches used to analyze metabolites from biological samples. SIMS uses a high-energy primary ion beam to desorb and generate secondary ions from a surface. The primary advantage of SIMS is its high spatial resolution (as small as 50 nm), a powerful characteristic for tissue imaging with MS. However, SIMS has yet to be readily applied to the analysis of biofluids and tissues because of its limited sensitivity at >500 Da and analyte fragmentation generated by the high-energy primary ion beam. Desorption electrospray ionization (DESI) is a matrix-free technique for analyzing biological samples that uses a charged solvent spray to desorb ions from a surface. Advantages of DESI are that no special surface is required and the analysis is performed at ambient pressure with full access to the sample during acquisition. A limitation of DESI is spatial resolution because "focusing" the charged solvent spray is difficult. However, a recent development termed laser ablation ESI (LAESI) is a promising approach to circumvent this limitation. Most recently, ion trap techniques such as orbitrap mass spectrometry are also applied to metabolomics research. Nuclear magnetic resonance (NMR) spectroscopy is the only detection technique which does not rely on separation of the analytes, and the sample can thus be recovered for further analyses. All kinds of small molecule metabolites can be measured simultaneously - in this sense, NMR is close to being a universal detector.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.